Track Assertio Holdings's EBIT ($-20M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowAs of Mar 31, 2026
Trailing 12 months ending Mar 31, 2026
The latest EBIT for ASRT is $-20M as of March 2026. That compares with $-30M in the prior-year period — up 34.7% year over year. That is below the Healthcare sector average of $22B. Investors often review this figure alongside Assertio Holdings's historical trend and sector peers before judging valuation or financial health.
Over the past year, ASRT's EBIT moved from $-30M to $-20M — a 34.7% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Assertio Holdings's operating scale or balance-sheet position.
Against Healthcare companies, ASRT currently prints $-20M for EBIT, while the sector average sits near $22B. That is roughly 100.1% below the sector mean. Large gaps often invite a closer look at Assertio Holdings's growth, margins, and balance sheet.
A EBIT figure of $-20M for ASRT is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $22B. Explore the charts below for those layers of context.
After noting ASRT's EBIT ($-20M), review year-over-year change from $-30M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.